Leela Barham, Author at

With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both deals on

The big squeeze?

https://pharmaphorum.com/market-access-2/the-big-squeeze/

Market Access/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Questions linger as England’s Innovative Medicines Fund kicks off

Leela Barham Innovative Medicines Fund, market access, NHS, NICE 0 Comment

In part one of this two-article series on the latest on England’s Innovative Medicines Fund (IMF), Leela Barham

Questions linger as England’s Innovative Medicines Fund kicks off

https://pharmaphorum.com/market-access-2/questions-linger-as-englands-innovative-medicines-fund-kicks-off/

Market Access/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

England’s Innovative Medicines Fund hits another milestone

Leela Barham Department of Health and Social Care, Innovative Medicines Fund, NHS 0 Comment

Leela Barham takes a look at the latest milestone on what will have been a close to three-year

England’s Innovative Medicines Fund hits another milestone

https://pharmaphorum.com/market-access-2/englands-innovative-medicines-fund-hits-another-milestone/

Market Access/ Views & Analysis/ Views and analysis

Why companies don’t submit to NICE

Leela Barham HTA, NICE, Non-submissions 0 Comment

In March 2022, Leela Barham argued that, in light of new highs in the number of non-submissions to

Why companies don’t submit to NICE

https://pharmaphorum.com/market-access-2/why-companies-dont-submit-to-nice/

Market Access/ Views & Analysis/ Views and analysis

Time to ask companies why they don’t submit to NICE?

Leela Barham ABPI, NICE, Voluntary Scheme for Branded Medicines Pricing and Access 0 Comment

Companies can choose whether or not to submit to NICE to have their products appraised. Many do, presumably

Time to ask companies why they don’t submit to NICE?

https://pharmaphorum.com/market-access-2/time-to-ask-companies-why-they-dont-submit-to-nice/

Market Access/ Views & Analysis/ Views and analysis

How do UK market access prospects look in 2022?

Leela Barham Brexit, Life Sciences, MHRA, NICE 0 Comment

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look

How do UK market access prospects look in 2022?

https://pharmaphorum.com/market-access-2/uk-market-access-prospects-2022/

Market Access/ Views & Analysis/ Views and analysis

Are we measuring what matters most on uptake to medicines in England?

Leela Barham ABPI, market access, VPAS 0 Comment

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful,

Are we measuring what matters most on uptake to medicines in England?

https://pharmaphorum.com/market-access-2/measuring-uptake-medicines-england/

Market Access/ Views & Analysis/ Views and analysis

Getting better at measuring international uptake of medicines?

Leela Barham ABPI, market access, VPAS 0 Comment

In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring

Getting better at measuring international uptake of medicines?

https://pharmaphorum.com/market-access-2/getting-better-at-measuring-international-uptake-of-medicines/

Market Access/ Views & Analysis/ Views and analysis

A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Leela Barham chronic fatigue syndrome, Myalgic encephalomyelitis, NICE 0 Comment

The work of the UK’s HTA body, the National Institute for Health and Care Excellence (NICE), is often

A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

https://pharmaphorum.com/views-and-analysis/guidelines-myalgic-encephalomyelitis-chronic-fatigue-syndrome/

Trending

About Leela Barham

Posts by Leela Barham:

The big squeeze?

Questions linger as England’s Innovative Medicines Fund kicks off

Why companies don’t submit to NICE

Time to ask companies why they don’t submit to NICE?

How do UK market access prospects look in 2022?

Are we measuring what matters most on uptake to medicines in England?

Getting better at measuring international uptake of medicines?

A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Trending

About Leela Barham

Posts by Leela Barham:

Login